Bacillus Coagulans Lactospore Mtcc5856
Also known as: LactoSpore, Bacillus coagulans MTCC 5856
Overview
*Bacillus coagulans* MTCC 5856 is a gram-positive, endospore-forming probiotic strain that is not a natural inhabitant of the human gut but is ingested as a dietary supplement. This spore-forming, thermostable bacterium is primarily used to manage symptoms of irritable bowel syndrome (IBS), specifically diarrhea-predominant IBS, and has also been investigated for its potential role in treating major depressive disorder (MDD) among IBS patients. Research indicates that it produces L(+) lactic acid, which helps inhibit pathogenic microbial growth in the gastrointestinal tract. The strain shows consistent genetic and phenotypic characteristics, and available evidence largely stem from well-conducted randomized controlled trials (RCTs) demonstrating its efficacy. Despite the growing body of research, further comprehensive systematic reviews are advised to consolidate current findings.
Benefits
Evidence demonstrates that *Bacillus coagulans* MTCC 5856 significantly reduces symptoms associated with diarrhea-predominant IBS, including bloating and abdominal pain, with p-values consistently below 0.01. It improves the quality of life and disease severity scores in IBS patients and shows promise in alleviating symptoms of functional gas and bloating, as evidenced by significant score improvements in population studies. Notably, individuals with concurrent major depressive disorder also report marked improvements in their symptoms. These benefits manifest within 4 to 90 days, depending on the specific condition treated, with significant clinical effects observed in various trials.
How it works
*Bacillus coagulans* MTCC 5856 operates through several biological mechanisms, primarily by producing L(+) lactic acid, which suppresses pathogenic bacterial growth in the gastrointestinal tract. It enhances the gut epithelial barrier function and modulates host immune responses. The strain improves gut microbiota composition, increasing beneficial bacterial diversity while reducing inflammatory biomarkers like serum myeloperoxidase, which contributes to inflammatory processes.
Side effects
Overall, *Bacillus coagulans* MTCC 5856 has an excellent safety profile, with no significant common side effects reported in research studies. No uncommon or rare side effects have been identified. Currently, no significant drug interactions have been documented. While there are no specific contraindications, caution is recommended for immunocompromised individuals, as with any probiotic. The safety and efficacy of this strain has not been extensively studied in pregnant or breastfeeding women, or in pediatric populations.
Dosage
The minimum effective dose for *Bacillus coagulans* MTCC 5856 is 2 × 10^9 cfu/day, which aligns with the optimal dosage range for experiencing significant health benefits. This dosage has shown efficacy in studies related to IBS and MDD symptoms. Although the maximum safe dose has not been definitively established, dosages up to 2 × 10^9 cfu/day have been considered safe. This probiotic strain can be consumed in tablet or capsule form, with each containing 2 billion spores, and does not require specific timing for consumption.
FAQs
How long does it take to see benefits?
Benefits can be observed within 4 to 90 days, depending on the condition treated.
Are there any side effects?
No significant side effects have been reported in studies involving *Bacillus coagulans* MTCC 5856.
Is it safe for everyone?
Generally, it is safe; however, caution is advised for immunocompromised individuals.
Can it be taken at any time?
Yes, it can be taken as part of a daily regimen without specific timing considerations.
What improvements can I expect?
Users typically report reductions in IBS symptoms, improvements in depression, and a decrease in gas and bloating.
Research Sources
- https://foodandnutritionresearch.net/index.php/fnr/article/view/1218 – This article summarizes the effects of *Bacillus coagulans* MTCC 5856 on major depressive disorder in IBS patients, demonstrating significant improvements in symptoms over a 90-day period through a randomized clinical trial.
- https://pubmed.ncbi.nlm.nih.gov/26922379/ – A study detailing the efficacy of *Bacillus coagulans* MTCC 5856 in newly diagnosed patients with diarrhea-predominant IBS, showcasing significant symptom reduction during a 90-day randomized controlled trial.
- https://www.springermedizin.de/bacillus-coagulans-mtcc-5856-supplementation-in-the-management-o/25658796 – This research highlights the impacts of *Bacillus coagulans* MTCC 5856 on functional gas and bloating, with results illustrating noteworthy reductions in indigestion subscale scores within a 4-week timeframe.
- https://pubmed.ncbi.nlm.nih.gov/36862903/ – The study offers insights into the interactions of *Bacillus coagulans* MTCC 5856 with the gut microbiota and its role in reducing inflammatory biomarkers associated with gastrointestinal disorders.
- https://journals.lww.com/md-journal/fulltext/2023/05190/probiotic_modulation_of_gut_microbiota_by_bacillus.53.aspx – This paper discusses the modulation of gut microbiota by *Bacillus coagulans* MTCC 5856, underlining its potential as a therapeutic agent in managing various gastrointestinal conditions.
